UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical use of dornase alfa is associated with a slower rate of FEV 1 decline in cystic fibrosis

Pediatric pulmonology, 2011-06, Vol.46 (6), p.545-553

2011

Volltextzugriff (PDF)

Cost-utility Analysis of Dornase alfa in comparison with Tobramycin for Managing Iranian Patients with Cystic Fibrosis

Journal of pharmacoeconomics and pharmaceutical management, 2023-06, Vol.9 (1)

Heydari, Fatemeh Sadat

2023

Volltextzugriff (PDF)

Self-reported chronic therapy use after 24-weeks of follow-up by participants who completed the simplify randomized, controlled trial

Journal of cystic fibrosis, 2024-09

2024

Volltextzugriff (PDF)

The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study

Journal of cystic fibrosis, 2024-05, Vol.23 (3), p.457-460

2024

Volltextzugriff (PDF)

Retrospective Evaluation of Intrapleural Tissue Plasminogen Activator With or Without Dornase Alfa for the Treatment of Traumatic Retained Hemothorax: A 6-Year Experience

The Annals of pharmacotherapy, 2022-11, Vol.56 (11), p.1222-1230

2022

Volltextzugriff (PDF)

Chronic daily respiratory care needs in people with cystic fibrosis treated with highly effective cystic fibrosis transmembrane conductance regulator modulators

Current opinion in pulmonary medicine, 2023-11, Vol.29 (6), p.580-586

2023

Volltextzugriff (PDF)

Refined DNase-seq protocol and data analysis reveals intrinsic bias in transcription factor footprint identification

Nature methods, 2014, Vol.11 (1), p.73-78

2014

Volltextzugriff (PDF)

Dornase alfa and progression of lung disease in cystic fibrosis

Pediatric pulmonology, 2008-09, Vol.43 (S9), p.S24-S28

Konstan, Michael W.

2008

Volltextzugriff (PDF)

Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome

New microbes and new infections, 2020-05, Vol.35, p.100689-100689, Article 100689

2020

Volltextzugriff (PDF)

Bladder cancer patients have increased NETosis and impaired DNaseI-mediated NET degradation that can be therapeutically restored in vitro

Frontiers in immunology, 2023-05, Vol.14, p.1171065-1171065

2023

Volltextzugriff (PDF)

PP-083 Compliance with dornase alfa post commencement of Kaftrio in a paediatric CF population

BMJ paediatrics open, 2024-07, Vol.8 (Suppl 5), p.A99-A100

2024

Volltextzugriff (PDF)

Clinical and functional control of mucolytic therapy in children with cystic fibrosis

Medicinskij sovet, 2022-04 (4), p.120-127

2022

Volltextzugriff (PDF)

Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series

Molecular medicine (Cambridge, Mass.), 2020-09, Vol.26 (1), p.91-91, Article 91

2020

Volltextzugriff (PDF)

Comparison of inhaled mannitol/dornase alfa combination and daily dornase alfa alone in children with cystic fibrosis

Pediatric pulmonology, 2022-01, Vol.57 (1), p.142-151

2022

Volltextzugriff (PDF)

The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis

The European respiratory journal, 2011-04, Vol.37 (4), p.806-812

2011

Volltextzugriff (PDF)

Resolution of lobe collapse in a child with cystic fibrosis with Mycobacterium abscessus using serial intrabronchial rhDNase

Pediatric pulmonology, 2022-06, Vol.57 (6), p.1549-1551

2022

Volltextzugriff (PDF)

Nebulization of PEGylated recombinant human deoxyribonuclease I using vibrating membrane nebulizers: A technical feasibility study

European journal of pharmaceutical sciences, 2023-10, Vol.189, p.106522-106522, Article 106522

2023

Volltextzugriff (PDF)

Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancer

PloS one, 2021-07, Vol.16 (7), p.e0254765-e0254765

2021

Volltextzugriff (PDF)

Safety, tolerability, and effect of a single aural dose of Dornase alfa at the time of ventilation tube surgery for otitis media: A Phase 1b double randomized control trial

International journal of pediatric otorhinolaryngology, 2024-02, Vol.177, p.111832-111832, Article 111832

2024

Volltextzugriff (PDF)

Preliminary report of in vitro and in vivo effectiveness of dornase alfa on SARS-CoV-2 infection

New microbes and new infections, 2020-09, Vol.37, p.100756, Article 100756

2020

Volltextzugriff (PDF)

Relapsing Plastic Bronchitis: A Brief Review of Currently Available Management Strategies

Clinical pulmonary medicine, 2019-07, Vol.26 (4), p.105-107

2019

Volltextzugriff (PDF)

Development of a Clonal and High-Yield Mammalian Cell Line for the Manufacturing of a Hyperactive Human DNase I with Extended Plasma Half-Life Using PASylation® Technology

Pharmaceutics, 2024-07, Vol.16 (7), p.967

2024

Volltextzugriff (PDF)

Comparison of FEV1 reference equations for evaluating a cystic fibrosis therapeutic intervention

Pediatric pulmonology, 2017-08, Vol.52 (8), p.1013-1019

2017

Volltextzugriff (PDF)

Withdrawal of dornase alfa increases ventilation inhomogeneity in children with cystic fibrosis

Journal of cystic fibrosis, 2021-11, Vol.20 (6), p.949-956

2021

Volltextzugriff (PDF)

1 – 25 von 117

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(102)
Mit Volltextzugriff
(98)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Dornase Alfa
(109)
Science & Technology
(76)
Life Sciences & Biomedicine
(73)
Cystic Fibrosis
(72)
Humans
(60)
Respiratory System
(37)
Pediatrics
(35)
Male
(28)
Cystic Fibrosis - Drug Therapy
(27)
Female
(26)
Child
(24)
Deoxyribonuclease I - Administration & Dosage
(23)
Biological And Medical Sciences
(22)
Medical Sciences
(22)
Deoxyribonuclease I - Therapeutic Use
(21)
Administration, Inhalation
(19)
Recombinant Proteins - Administration & Dosage
(17)
Adolescent
(16)
Recombinant Proteins - Therapeutic Use
(16)
Patients
(15)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Clinical use of dornase alfa is associated with a slower rate of FEV 1 decline in cystic fibrosis

Cost-utility Analysis of Dornase alfa in comparison with Tobramycin for Managing Iranian Patients with Cystic Fibrosis

Self-reported chronic therapy use after 24-weeks of follow-up by participants who completed the simplify randomized, controlled trial

The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study

Retrospective Evaluation of Intrapleural Tissue Plasminogen Activator With or Without Dornase Alfa for the Treatment of Traumatic Retained Hemothorax: A 6-Year Experience

Chronic daily respiratory care needs in people with cystic fibrosis treated with highly effective cystic fibrosis transmembrane conductance regulator modulators

Refined DNase-seq protocol and data analysis reveals intrinsic bias in transcription factor footprint identification

Dornase alfa and progression of lung disease in cystic fibrosis

Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome

Bladder cancer patients have increased NETosis and impaired DNaseI-mediated NET degradation that can be therapeutically restored in vitro

PP-083 Compliance with dornase alfa post commencement of Kaftrio in a paediatric CF population

Clinical and functional control of mucolytic therapy in children with cystic fibrosis

Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series

Comparison of inhaled mannitol/dornase alfa combination and daily dornase alfa alone in children with cystic fibrosis

The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis

Resolution of lobe collapse in a child with cystic fibrosis with Mycobacterium abscessus using serial intrabronchial rhDNase

Nebulization of PEGylated recombinant human deoxyribonuclease I using vibrating membrane nebulizers: A technical feasibility study

Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancer

Anti-inflammatory therapy with nebulized dornase alfa for severe COVID-19 pneumonia: a randomized unblinded trial

Safety, tolerability, and effect of a single aural dose of Dornase alfa at the time of ventilation tube surgery for otitis media: A Phase 1b double randomized control trial

Preliminary report of in vitro and in vivo effectiveness of dornase alfa on SARS-CoV-2 infection

Relapsing Plastic Bronchitis: A Brief Review of Currently Available Management Strategies

Development of a Clonal and High-Yield Mammalian Cell Line for the Manufacturing of a Hyperactive Human DNase I with Extended Plasma Half-Life Using PASylation® Technology

Comparison of FEV1 reference equations for evaluating a cystic fibrosis therapeutic intervention

Withdrawal of dornase alfa increases ventilation inhomogeneity in children with cystic fibrosis

Suchergebnisse filtern